MARIA MITZI BRENTANI
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
- Somatic mutations in early onset luminal breast cancer(2018) ENCINAS, G.; SABELNYKOVA, V. Y.; LYRA, E. C. de; KATAYAMA, M. L. H.; MAISTRO, S.; VALLE, P. W. M. V.; PEREIRA, G. F. L.; RODRIGUES, L. M.; SERIO, P. A. M. P.; GOUVêA, A. C. R. C. de; GEYER, F. C.; BASSO, R. A.; PASINI, F. S.; DIZ, M. P. E.; BRENTANI, M. M.; GóES, J. C. G. S.; CHAMMAS, R.; BOUTROS, P. C.; FOLGUEIRA, M. A. A. K.Breast cancer arising in very young patients may be biologically distinct; however, these tumors have been less well studied. We characterized a group of very young patients (≤ 35 years) for BRCA germline mutation and for somatic mutations in luminal (HER2 negative) breast cancer. Thirteen of 79 unselected very young patients were BRCA1/2 germline mutation carriers. Of the non-BRCA tumors, eight with luminal subtype (HER2 negative) were submitted for whole exome sequencing and integrated with 29 luminal samples from the COSMIC database or previous literature for analysis. We identified C to T single nucleotide variants (SNVs) as the most common base-change. A median of six candidate driver genes was mutated by SNVs in each sample and the most frequently mutated genes were PIK3CA, GATA3, TP53 and MAP2K4. Potential cancer drivers affected in the present non-BRCA tumors include GRHL2, PIK3AP1, CACNA1E, SEMA6D, SMURF2, RSBN1 and MTHFD2. Sixteen out of 37 luminal tumors (43%) harbored SNVs in DNA repair genes, such as ATR, BAP1, ERCC6, FANCD2, FANCL, MLH1, MUTYH, PALB2, POLD1, POLE, RAD9A, RAD51 and TP53, and 54% presented pathogenic mutations (frameshift or nonsense) in at least one gene involved in gene transcription. The differential biology of luminal early-age onset breast cancer needs a deeper genomic investigation. © Encinas et al.
- Claudin 4 and 7 Expression Is Not Correlated to Triple Negative Phenotype in Invasive NOS Breast Carcinomas: A Wide Series Assessed by Immunohistochemistry(2014) LOGULLO, A. F.; STIEPCICH, M. A.; NONOGAKI, S.; MALAGOLI, R.; BRENTANI, M. M.; PASINI, F. S.; SOARES, F. A.
conferenceObject Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?(2018) MUNDIM, F.; FRANCO, A.; INFANTE, K.; NETO, J.; BRENTANI, M. M.; FACINA, G.; WAITZBERG, A.- HER2-associated lipogenic phenotype as a potential therapeutical target in breast cancer patients(2017) RAVACCI, G. R.; SANTOS, J. R.; BRENTANI, M. M.; TORTELLI, T.; DALE, I.; LOGULLO, A. F.; WAITZBERG, D. L.
conferenceObject Ipsilateral breast cancer recurrence in conservative treatment for locally advanced breast cancer(2015) CARRARA, G. F. A.; NETO, C. S.; ABRAO-MACHADO, L. F.; NUNES, J. S.; FOLGUEIRA, M. A. A. K.; BRENTANI, M. M.; VIEIRA, R. A. C.- Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer(2012) BERNARDI, M. A.; LOGULLO, A. F.; PASINI, F. S.; NONOGAKI, S.; BLUMKE, C.; SOARES, F. A.; BRENTANI, M. M.This study aimed to identify the CD24 and CD44 immunophenotypes within invasive ductal breast carcinoma (I DC) subgroups defined by immunohistochesmistry markers and to determine its influence on prognosis as well as its association with the expression of Ki-67, cytokeratins (CK5 and CK 18) and claudin-7. Immunohistochemical expression of CD44 and CD24 alone or in combination was investigated in 95 IDC cases arranged in a tissue microarray (TMA). The association with subgroups defined as luminal A and B; HER2 rich and triple negative, or with the other markers and prognosis was analyzed. CD44(+)/CD24(-) and CD44(-)/CD24(+) were respectively present in 8.4% and 16.8% of the tumors, a lack of both proteins was detected in 6.3%, while CD441(-)/CD24(+) was observed in 45.3% of the tumors. Although there was no significant correlation between subgroups and different phenotypes, the CD44(+)/CD24(-) phenotype was more common in the basal subgroups but absent in HER2 tumors, whereas luminal tumors are enriched in CD44(-)/CD24(+) and CD44(+)/CD24(+) cells. The frequency of CD44(+)/CD24(-) or CD44(-)/CD24(+) was not associated with clinical characteristics or biological markers. There was also no significant association of these phenotypes with the event free (DFS) and overall survival (OS). Single CD44(+) was evident in 57.9% of the tumors and was marginally associated to grading and not to any other tumor characteristics as well as OS and DFS. CD24(+) was positive in 74.7% of the tumors, showing a significant association with estrogen receptor, progesterone receptor and Ki-67 and a marginal association with CKI8 and claudin-7. Expression of claudin-7 and Ki-67 did not associate with the cancer subgroups, while a positive association between CK18 and the luminal subgroups was found (P=0.03). CK5, CK18 and Ki-67 expression had no influence in OS or DFS. Single CD24(+) (P=0.07) and claudin-7 positivity (P=0.05) were associated with reduced time of recurrence, suggesting a contribution of these markers to aggressiveness of breast cancer.
- Claudin 4 and 7 Expression Is Not Correlated to Triple Negative Phenotype in Invasive NOS Breast Carcinomas: A Wide Series Assessed by Immunohistochemistry(2014) LOGULLO, A. F.; STIEPCICH, M. A.; NONOGAKI, S.; MALAGOLI, R.; BRENTANI, M. M.; PASINI, F. S.; SOARES, F. A.
conferenceObject BASELINE STAGING TESTS FOR LOCALLY ADVANCED BREAST CANCER(2013) VIEIRA, R. A. C.; GARCIA, G. F.; ZUCCA-MATTHES, A. G.; UEMURA, G.; BRENTANI, M. M.; FOLGUEIRA, M. A. A. K.Goals: To evaluate the impact of different radiological exams in the clinical staging of locally advanced breast cancer (LABC) and the possibility to evaluate bone metastasis with computed tomography (CT) in substitution of scintigraphy. Methods: A prospective clinical trial (www.clinicaltrials.gov; NCT00820690) performed in breast cancer women during 06/2008 to 05/2011. Patients with invasive carcinoma, clinical stage III, absence of systemic symptoms and absence of previous treatment were included. Exclusion criteria were the absence of invasive disease, staging exams and follow-up. The patients were submitted to a clinical examination, mammography, breast ultrasound and biopsy. To evaluate the presence of metastatic disease the patients were submitted to chest X-Ray, abdominal ultrasound, bone scintigraphy (conventional exams) and CT (abdominal and thoracic). In the presence of suspicion exams, complementary exams were performed. If the CT needs control, new exams were performed. All patients were submitted to neoadjuvant or palliative chemotherapy. At the end of study one radiologist reviewed all exams and medical reports. We evaluated the frequency of metastasis in the conventional exams and when the patients were evaluated with CT. Results: 148 patients were enrolled, but 10 patients were excluded. From the 138 patients, the median tumor size was 6.6cm (3–15cm). Evaluating the clinical stage (TNM) there were 60.9% cT3, 38.4% cT4, 67.4% cN1, 25.4% cN2 and 2.2% cN3. After all exams performed 38 (28.3%) had metastatic disease. When we use conventional exams8.7%hadmetastaticdisease,but17.4%neededcomplementary exams, leading to 13.8% [IC=8.08–19.55] of metastatic disease. When we use CT (abdominal and thoracic) and scintigraphy for staging, 28.3% [IC=20.8–34.9] had metastatic disease, with an increase of 14.5% of diagnosis of metastatic disease. The CT showed 6 patients (4.3%) with bone metastasis and normal scintigraphy, but it did not increased the frequency of metastatic disease. Conclusion: Patients with LABC must be evaluated with a minimum of CT (abdominal and thoracic) added to the bone scintigraphy. The conventional exams decreased 14.5% of the metastatic disease diagnosis and the CT increased 4.3% of diagnosis of bone metastasis. Disclosure of Interest: No significant relationships.- The effects of urban particulate matter on the nasal epithelium by gender: An experimental study in mice(2016) YOSHIZAKI, K.; FUZIWARA, C. S.; BRITO, J. M.; SANTOS, T. M. N.; KIMURA, E. T.; CORREIA, A. T.; AMATO-LOURENCO, L. F.; VASCONCELLOS, P.; SILVA, L. F.; BRENTANI, M. M.; MAUAD, T.; SALDIVA, P. H. N.; MACCHIONE, M.Nose is the first portion of the respiratory system into contact with air pollution particles, including organic compounds that could act as endocrine releasers. The objective was to identify and quantify estrogenic receptor-beta (ER beta), aryl hydrocarbon receptor (AhR), the cytochrome P450 enzymes CYP1A1, 1A2, 1B1, and mucus profile in the nasal epithelium of mice. BALB/c mice male (n = 32) and female (n = 82) in proestrus, estrus and diestrus were divided into two groups: 1) exposed to ambient air; 2) concentrated ambient particles (CAPs) to achieve an accumulated dose (concentration vs. time product) of 600 mu g/m(3), the time of the exposure was controlled to ensure the same concentration for all groups (5 days per week for 40-51 days). RT-PCR (Er beta-1, Er beta-2, Ahr, Cyp1a1, Cyp1a2, Cyp1b1), immunohistochemistry and morphometry (ER(3, AhR) were used to analyze. The mucus profiles were examined using acid (Aldan Blue) and neutral (periodic acid Schiff's) stains. Exposed females had significantly lower levels of Er beta-2 mRNA than exposed males (p = 0.036). Cyp1b1 mRNA in diestrus females was significantly lower in the CAP-exposed group compared with the ambient air group (p <= 0.05). ER beta expression in the epithelium and submucosa nucleus was lower in estrus exposed to CAPs compared with ambient air. CAPs increases AhR in the epithelium (p = 0.044) and submucosa (p = 0.001) nucleus of female when compared with male mice. Exposure to CAPs, also led to relatively increased acidic content in the mucus of males (p = 0.048), but decreased acidic content in that of females (p = 0.04). This study revealed sex dependent responses to air pollution in the nasal epithelium that may partially explain the predisposition of females to airway respiratory diseases.
- Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes(2014) NAGAI, M. A.; BRENTANI, M. M.The estrogens play important role in the homeostatic maintenance of several target tissues including those in the mammary gland, uterus, bone, cardiovascular system, and brain. Most of estrogen's action is thought to be mediated through its nuclear estrogen receptors, ERα and ERβ, which are members of the nuclear receptor superfamily that act as ligand-induced transcription factors. Acting via its receptors, estrogen also plays an essential role in the development and progression of human breast cancer. The ER and progesterone receptor (PR), which is regulated by estrogen via ER, have been used as prognostic markers in the clinical management of breast cancer patients. However, the prognosis of a patient with ER+/PR+ breast cancer can be highly variable and a significant proportion of hormone receptor positive breast cancers do not respond to endocrine therapy. The identification of estrogen receptor target genes may improve our understanding of the role played by estrogens in breast cancer making it possible to better tailor hormone treatments and improve a patient's response to hormonal therapy. In this review, we explore the literature for data regarding the identification of estrogen receptor-regulated genes in breast cancer cell lines and breast tumor biopsies using high throughput technologies such as serial analysis of gene expression (SAGE) and cDNA microarrays. © 2014 Bentham Science Publishers Ltd. Published by Elsevier Inc. All rights reserved.